Corporate ActionMay 4, 2026, 06:39 AM
Cabaletta Bio prices $150M underwritten common stock offering
AI Summary
Cabaletta Bio, a clinical-stage biotechnology company, announced the pricing of an underwritten public offering of 51,725,000 shares of its common stock at $2.90 per share. The offering is expected to generate approximately $150 million in gross proceeds and is anticipated to close around May 5, 2026. Key investors, including Bain Capital Life Sciences, Adage Capital Management, Cormorant Asset Management, new funds, and Eli Lilly and Company, participated in the financing.
Key Highlights
- Cabaletta Bio priced an underwritten offering of 51,725,000 shares of common stock.
- The offering is expected to generate approximately $150 million in gross proceeds.
- The common stock was priced at $2.90 per share.
- Key participants include Bain Capital Life Sciences, Adage Capital Management, Cormorant Asset Management, and Eli Lilly and Company.
- The offering is anticipated to close on or about May 5, 2026.